{
    "name": "dasiglucagon",
    "comment": "Rx",
    "other_names": [
        "Zegalogue"
    ],
    "classes": [
        "Glucose-Elevating Agents",
        "Hypoglycemia Antidotes"
    ],
    "source": "https://reference.medscape.com/drug/zegalogue-dasiglucagon-4000161",
    "pregnancy": {
        "common": [
            "There are no available data on use in pregnant females to evaluate for drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Untreated hypoglycemia in pregnancy can cause complications and may be fatal"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Daily SC administration to pregnant rabbits and rats during organogenesis did not cause adverse developmental effects at exposures 7 and 709 times the human dose of 0.6 mg based on AUC, respectively"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There is no information available on presence in human or animal milk, effects on breastfed children, or on milk production",
            "Dasiglucagon is a peptide and would be expected to be broken down to its constituent amino acids in infant's digestive tract, and is therefore unlikely to cause harm to an exposed infant"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Pheochromocytoma",
                "Insulinoma"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Contraindicated with pheochromocytoma; glucagon may stimulate catecholamine release from the tumor; if substantial increase in blood pressure develops, phentolamine mesylate 5-10 mg IV has been shown to be effective in lowering blood pressure ",
                "Generalized allergic reactions, including urticaria, respiratory distress, hypotension, and in some cases anaphylactic shock, reported with glucagon products; if symptoms occur, discontinue and treat as indicated",
                "Treatment for hypoglycemia only effective if sufficient hepatic glycogen present; patients in states of starvation, with adrenal insufficiency, or chronic hypoglycemia may not have adequate levels of hepatic glycogen for therapy to be effective; treat these conditions with glucose"
            ],
            "specific": [
                {
                    "type": "Insulinoma",
                    "description": [
                        "Contraindicated with insulinoma",
                        "Glucagon may initially produce increased glucose; however, administration may directly or indirectly (via initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia",
                        "If hypoglycemia develops following administration, give PO or IV glucose"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Beta-blockers",
                        "Use with caution",
                        "Beta-blockers may cause transient increases in pulse and blood pressure",
                        "Indomethacin",
                        "Use with caution",
                        "When used with indomethacin, glucagon may lose its ability to raise blood glucose or may even produce hypoglycemia",
                        "Warfarin",
                        "Use with caution",
                        "Glucagon may increase anticoagulant effect of warfarin"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acebutolol",
            "description": {
                "common": "acebutolol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atenolol",
            "description": {
                "common": "atenolol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betaxolol",
            "description": {
                "common": "betaxolol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "bisoprolol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celiprolol",
            "description": {
                "common": "celiprolol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esmolol",
            "description": {
                "common": "esmolol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "indomethacin decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "metoprolol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nadolol",
            "description": {
                "common": "nadolol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "nebivolol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penbutolol",
            "description": {
                "common": "penbutolol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pindolol",
            "description": {
                "common": "pindolol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "propranolol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotalol",
            "description": {
                "common": "sotalol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "timolol",
            "description": {
                "common": "timolol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "57"
        },
        {
            "name": "Vomiting",
            "percent": "25"
        },
        {
            "name": "Headache",
            "percent": "11"
        },
        {
            "name": "Nausea",
            "percent": "92"
        },
        {
            "name": "Vomiting",
            "percent": "67"
        },
        {
            "name": "Headache",
            "percent": "17"
        },
        {
            "name": "Nausea",
            "percent": "25"
        },
        {
            "name": "Vomiting",
            "percent": "25"
        },
        {
            "name": "Diarrhea",
            "percent": "5"
        },
        {
            "name": "Injection site pain",
            "percent": "2"
        },
        {
            "name": "Injection site pain",
            "percent": "8"
        }
    ]
}